Esperion says FDA won't commit to surrogate endpoint

Esperion Therapeutics Inc. (NASDAQ:ESPR) lost $4.40 (27%) to $11.78 in early after-hours trading Tuesday after it said FDA "did not provide clarity on a regulatory pathway" in dialogue with the

Read the full 308 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE